Business
Nemaura Signs Heads of Terms for sugarBEAT® with Device Technologies for Australia and New Zealand
Nemaura Signs Heads of Terms for sugarBEAT® with Device Technologies for Australia and New Zealand.
About this update from Nemaura Medical, Inc.
[{"type":"text","content":"\n \n Nemaura Medical Inc. (OTCQB: NMRD), a medical technology company focused \n on the development and commercialization of sugarBEAT®, a wireless \n disposable adhesive skin-patch for adjunctive use by diabetics as a \n non-invasive and needle-free continuous glucose monitoring (CGM) system \n announced today it has signed a non-binding term sheet with Device \n Technologies for exclusive rights to market and sell sugarBEAT® in \n Australia and New Zealand.\n \n \n Device Technologies is a leading Medical Device distributor employing \n over 600 healthcare specialists and support staff in Australia and New \n Zealand. Dr Faz Chowdhury CEO of Nemaura Medical comments, “Device \n Technologies have a strong understanding of complex and novel medical \n devices and are well positioned to successfully commercialise sugarBEAT® \n in Australia and New Zealand”.\n \n \n Nemaura Medical expect to launch in Australia and New Zealand in 2018, \n following an anticipated initial launch in UK in 2017.\n \n \n About Nemaura Medical, Inc.\n \n \n Nemaura Medical is a medical technology company developing the wireless \n sugarBEAT® disposable adhesive skin-patch as a non-invasive, \n needle-free, pain-free and affordable continuous glucose monitoring \n (CGM) system for adjunctive use by diabetics. For more information, \n please visit www.nemauramedical.com.\n \n \n Cautionary Statement Regarding Forward Looking Statements\n \n \n The statements in this press release that are not historical facts, and \n may constitute forward-looking statements that are based on current \n expectations and are subject to risks and uncertainties that could cause \n actual future results to differ materially from those expressed or \n implied by such statements. Those risks and uncertainties include, but \n are not limited to, risks related to regulatory approvals and the \n success of Nemaura Medical’s ongoing studies, including the safety and \n efficacy of Nemaura Medical’s sugarBEAT® CGM system, the failure of \n future development and preliminary marketing efforts, Nemaura Medical’s \n ability to secure additional commercial partnering arrangements, risks \n and uncertainties relating to Nemaura Medical and its partners’ ability \n to develop, market and sell sugarBEAT®, the availability ...